CR20130643A - Combinación que comprende umeclidinio y un corticosteroide - Google Patents

Combinación que comprende umeclidinio y un corticosteroide

Info

Publication number
CR20130643A
CR20130643A CR20130643A CR20130643A CR20130643A CR 20130643 A CR20130643 A CR 20130643A CR 20130643 A CR20130643 A CR 20130643A CR 20130643 A CR20130643 A CR 20130643A CR 20130643 A CR20130643 A CR 20130643A
Authority
CR
Costa Rica
Prior art keywords
combination
corticosteroid
umeclidinium
receptor
muscarinic
Prior art date
Application number
CR20130643A
Other languages
English (en)
Inventor
Glenn Crater
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CR20130643A publication Critical patent/CR20130643A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención está dirigida a la combinación de un antagonista del receptor muscarínico y un corticosteroide, y al uso de dicha combinación en el tratamiento de enfermedades mediadas a través del receptor muscarínico de acetilcolina M3, y/o el receptor glucocorticoide, tales como el asma.
CR20130643A 2011-06-08 2013-12-09 Combinación que comprende umeclidinio y un corticosteroide CR20130643A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161494600P 2011-06-08 2011-06-08

Publications (1)

Publication Number Publication Date
CR20130643A true CR20130643A (es) 2014-02-04

Family

ID=46201674

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20130643A CR20130643A (es) 2011-06-08 2013-12-09 Combinación que comprende umeclidinio y un corticosteroide

Country Status (20)

Country Link
US (1) US20140113888A1 (es)
EP (1) EP2717868A1 (es)
JP (1) JP2014516062A (es)
KR (1) KR20140041699A (es)
CN (1) CN103582477A (es)
AU (1) AU2012266541A1 (es)
BR (1) BR112013031572A2 (es)
CA (1) CA2838030A1 (es)
CL (1) CL2013003497A1 (es)
CO (1) CO6821951A2 (es)
CR (1) CR20130643A (es)
DO (1) DOP2013000290A (es)
EA (1) EA201391618A1 (es)
IL (1) IL229633A0 (es)
MA (1) MA35406B1 (es)
MX (1) MX2013014399A (es)
PE (1) PE20141048A1 (es)
PH (1) PH12013502497A1 (es)
SG (1) SG195262A1 (es)
WO (1) WO2012168161A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3578169T3 (pl) 2009-02-26 2024-09-02 Glaxo Group Limited Preparaty farmaceutyczne zawierające 4-{(1r)-2-[(6-{2-[(2,6-dichlorobenzylo)oksy]etoksy}heksylo)amino]-1-hydroksyetylo}-2-(hydroksymetylo)fenol
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
ES2778108T3 (es) 2011-12-28 2020-08-07 Asahi Chemical Ind Uso de una membrana de electrolito en una batería secundaria de flujo rédox
BR112014025518B1 (pt) 2012-04-13 2022-05-24 Glaxosmithkline Intellectual Property Development Limited Partículas agregadas de umeclidinium, vilanterol e fluticasona, composição em pó, inalador, processo para a preparação de partículas agregadas, e, uso de estearato de magnésio em partículas agregadas
GB201222679D0 (en) 2012-12-17 2013-01-30 Glaxo Group Ltd Pharmaceutical combination products
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
US10987363B2 (en) 2014-05-28 2021-04-27 Glaxosmithkline Intellectual Property Development Limited Fluticasone furoate in the treatment of COPD
CA2952760A1 (en) 2014-06-18 2015-12-23 Cipla Limited Pharmaceutical composition comprising a beta-2-agonist and anticholinergic agent
CN107200734B (zh) * 2016-03-18 2019-12-24 益方生物科技（上海）有限公司 奎宁环衍生物及其制备方法和用途
TR201712424A2 (tr) * 2017-08-21 2019-03-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Kuru toz i̇nhalasyon bi̇leşi̇mleri̇
WO2021236570A1 (en) * 2020-05-18 2021-11-25 Anovent Pharmaceutical (U.S.), Llc Pharmaceutical formulation containing remdesivir and its active metabolites for dry powder inhalation
AU2021351695A1 (en) * 2020-10-02 2023-06-08 Colgate-Palmolive Company Prebiotic oral care compositions and methods
TR2024005397A2 (tr) * 2024-05-04 2025-11-21 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Umeklidinyum?un Kuru Toz İnhaler Bileşimi.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
AU679511B2 (en) 1993-03-17 1997-07-03 Minnesota Mining And Manufacturing Company Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
PT1305329E (pt) 2000-08-05 2007-12-24 Glaxo Group Ltd Éster s-fluorometílico do ácido 6.alfa.,9.alfa.-difluoro- 17.alfa.-(2-furanilcarboxil)oxi-11.beta.-hidroxi-16.alfa.-metil- 3-oxo-androsta-1,4-dieno-17-carbotióico como um agente antiinflamatório
UA77656C2 (en) * 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
SE527191C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av tiotropium och fluticason
AR050902A1 (es) 2004-04-27 2006-12-06 Glaxo Group Ltd Compuesto de quinuclidina, composicion farmaceutica que lo comprende y su usopara preparar dicha composicion
PE20060826A1 (es) * 2004-12-06 2006-10-08 Smithkline Beecham Corp Derivado oleofinico de 8-azoniabiciclo[3.2.1]octano y combinacion farmaceutica que lo comprende
GB0515584D0 (en) 2005-07-28 2005-09-07 Glaxo Group Ltd Medicament dispenser
AR058289A1 (es) 2005-12-12 2008-01-30 Glaxo Group Ltd Colector para ser usado en dispensador de medicamento
KR20100063116A (ko) * 2007-09-12 2010-06-10 글락소 그룹 리미티드 치료제들의 복합제
PL3578169T3 (pl) * 2009-02-26 2024-09-02 Glaxo Group Limited Preparaty farmaceutyczne zawierające 4-{(1r)-2-[(6-{2-[(2,6-dichlorobenzylo)oksy]etoksy}heksylo)amino]-1-hydroksyetylo}-2-(hydroksymetylo)fenol
GB0921075D0 (en) * 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents

Also Published As

Publication number Publication date
MA35406B1 (fr) 2014-09-01
EA201391618A1 (ru) 2014-05-30
KR20140041699A (ko) 2014-04-04
NZ618166A (en) 2016-01-29
EP2717868A1 (en) 2014-04-16
PH12013502497A1 (en) 2019-07-17
CN103582477A (zh) 2014-02-12
PE20141048A1 (es) 2014-09-08
JP2014516062A (ja) 2014-07-07
AU2012266541A1 (en) 2014-01-09
DOP2013000290A (es) 2014-03-16
CA2838030A1 (en) 2012-12-13
US20140113888A1 (en) 2014-04-24
IL229633A0 (en) 2014-01-30
CL2013003497A1 (es) 2014-07-04
SG195262A1 (en) 2013-12-30
CO6821951A2 (es) 2013-12-31
BR112013031572A2 (pt) 2017-03-21
WO2012168161A1 (en) 2012-12-13
MX2013014399A (es) 2014-03-21

Similar Documents

Publication Publication Date Title
CR20130643A (es) Combinación que comprende umeclidinio y un corticosteroide
ECSP11011163A (es) Pirimidin-4-carboxamidas cíclicas en calidad de antagonistas del receptor CCR2 para el tratamiento de inflamación, asma y EPOC
PY1337526A (es) Métodos para tratar o prevenir asma administrando un antagonista de IL-4R.
UY35013A (es) Composiciones farmacéuticas que contienen un antagonista de il-4r y sus usos
NI201500004A (es) Métodos y composiciones para determinar la resistencia a la terapia con receptor de andrógeno.
ECSP12012010A (es) Nuevos antagonistas del receptor CCR2 y usos de los mismos.
GT200900016A (es) 2-fenilo-indoles como antagonistas del receptor de la prostaglandina d2
DOP2012000166A (es) Aminopirimidinas como inhibidores de syk
PH12016500953A1 (en) Tricyclic compounds as anticancer agents
UY30917A1 (es) Moduladores 2-aminopiridina del receptor histamina h
PH12014502095A1 (en) Estrogen receptor modulators and uses thereof
CL2015002616A1 (es) 7-azabiciclos sustituidos y su uso como modulares del receptor de orexina.
CL2008000307A1 (es) Compuestos derivados de cromen-2-ona sustituido; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como ateroesclerosis, asma, rinitis alergica y epoc.
PE20141792A1 (es) Formas polimorficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluor-3-fenilquinazolin-4(3h)-ona
GT201300122A (es) Antagonistas del receptor del cgrp de piperidinona carboxamida azaindano
MX2015011132A (es) Moduladores policiclicos del receptor de estrogenos y sus usos.
CR20130632A (es) El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico
CL2015001202A1 (es) Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.
DOP2014000114A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
AR093939A1 (es) Composiciones que comprenden vortioxetina y donepezil
CL2013003625A1 (es) Compuestos derivados de tetrahidroquinolinas condensadas con un cicloalquilo; formulacion farmaceutica que los comprende; y uso como moduladores de receptores de crth2 en el tratamiento del asma, rinitis alergica o epoc.
DOP2017000058A (es) Derivados de tetrahidroquinolina como inhibidores del bromodominio
MX2014005651A (es) Composiciones de poliolefinas autoemulsionantes.
GT201600190A (es) Compuestos químicos
GR20120100608A (el) Προ-συναρμολογημενη εκθεσιακη κατασκευη